Transamniotic Delivery of Hematopoietic Stem Cells Genetically Modified to Carry a Human Hemoglobin Subunit Beta Gene (HBB) in a Healthy Rodent Model

Investigators determined whether transamniotic stem cell therapy could be a viable alternative for the fetal administration of genetically modified hematopoietic stem cells carrying a human HBB in a healthy syngeneic rat model.